Detail

Basic Information Clinical Results Relationship Graph

Gene symbol	KDR	Synonyms	CD309, FLK1, VEGFR, VEGFR2	Type of gene	protein-coding
Chromosome	4	Map location	4q12	dbXrefs
Gene perturbation-related omics dataset	PertOrg
Description	kinase insert domain receptor

GTO ID	GTC0103
Trial ID	NCT01218867
Disease	Renal Carcinoma \| Metastatic Melanoma
Altered gene	VEGFR2
Therapeutic/Target gene	Target gene
Therapy	CAR-T cell
Treatment	VEGFR2 CAR-T cells
Phase	Phase1\|Phase2
Recruitment status	Terminated
Title	CAR T Cell Receptor Immunotherapy Targeting VEGFR2 for Patients With Metastatic Cancer
Year	2010
Country	United States
Company sponsor	National Cancer Institute (NCI)
Other ID(s)	110013\|11-C-0013

Vector information

Vector	retrovirus
Transgene/Inserted gene	anti-vascular endothelial growth factor receptor (VEGFR2) gene

Cohort1: dose level 1_High Dose IL-2

Administration route	intravenous infusion
Dosage	1E6 cells
Donor type	Autologous
Pts	1
Age	Adult, Older_Adult
Lymph depletion	Yes
Outcome	1/1(SD)
Adverse reactions	no any CAR-T-related severe events

Cohort2: dose level 2_High Dose IL-2

Administration route	intravenous infusion
Dosage	3E6 cells
Donor type	Autologous
Pts	1
Age	Adult, Older_Adult
Lymph depletion	Yes
Outcome	1/1(SD)
Adverse reactions	no any CAR-T-related severe events

Cohort3: dose level 3_High Dose IL-2

Administration route	intravenous infusion
Dosage	1E7 cells
Donor type	Autologous
Pts	3
Age	Adult, Older_Adult
Lymph depletion	Yes
Outcome	3/3(SD)
Adverse reactions	1/3(Gastrointestinal disorders; General disorders)

Cohort4: dose level 4_High Dose IL-2

Administration route	intravenous infusion
Dosage	3E7 cells
Donor type	Autologous
Pts	1
Age	Adult, Older_Adult
Lymph depletion	Yes
Outcome	1/1(SD)
Adverse reactions	no any CAR-T-related severe events

Cohort5: dose level 5_High Dose IL-2

Administration route	intravenous infusion
Dosage	1E8 cells
Donor type	Autologous
Pts	1
Age	Adult, Older_Adult
Lymph depletion	Yes
Outcome	1/1(SD)
Adverse reactions	1/1(Metabolism and nutrition disorders)

Cohort6: dose level 6_High Dose IL-2

Administration route	intravenous infusion
Dosage	3E8 cells
Donor type	Autologous
Pts	1
Age	Adult, Older_Adult
Lymph depletion	Yes
Outcome	1/1(SD)
Adverse reactions	no any CAR-T-related severe events

Cohort7: dose level 7_High Dose IL-2

Administration route	intravenous infusion
Dosage	1E9 cells
Donor type	Autologous
Pts	4
Age	Adult, Older_Adult
Lymph depletion	Yes
Outcome	3/4(SD); 1/4(PD)
Adverse reactions	3/4(Infections and infestations; Metabolism and nutrition disorders; Respiratory, thoracic and mediastinal disorders)

Cohort8: dose level 7_Low Dose IL-2

Administration route	intravenous infusion
Dosage	1E9 cells
Donor type	Autologous
Pts	3
Age	Adult, Older_Adult
Lymph depletion	Yes
Outcome	3/3(SD)
Adverse reactions	no any CAR-T-related severe events

Cohort9: dose level 8_Low Dose IL-2

Administration route	intravenous infusion
Dosage	3E9 cells
Donor type	Autologous
Pts	3
Age	Adult, Older_Adult
Lymph depletion	Yes
Outcome	3/3(SD)
Adverse reactions	no any CAR-T-related severe events

Cohort10: dose level 9_Low Dose IL-2

Administration route	intravenous infusion
Dosage	1E10 cells
Donor type	Autologous
Pts	4
Age	Adult, Older_Adult
Lymph depletion	Yes
Outcome	1/4(PR); 3/4(SD)
Adverse reactions	no any CAR-T-related severe events

Cohort11: dose level 10_Low Dose IL-2

Administration route	intravenous infusion
Dosage	3E10 cells
Donor type	Autologous
Pts	2
Age	Adult, Older_Adult
Lymph depletion	Yes
Outcome	2/2(SD)
Adverse reactions	no any CAR-T-related severe events

Overview of Knowledge Graph